Skip to main content
. 2019 Sep 3;8(9):1380. doi: 10.3390/jcm8091380

Figure 1.

Figure 1

Kaplan–Meier curves for cancer recurrence and overall survival of patients treated with and without palonosetron or ramosetron. P-R group patients were treated with ramosetron or palonosetron perioperatively. No P-R group patients were treated without ramosetron and palonosetron perioperatively.